JP7185524B2 - Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 - Google Patents

Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 Download PDF

Info

Publication number
JP7185524B2
JP7185524B2 JP2018513423A JP2018513423A JP7185524B2 JP 7185524 B2 JP7185524 B2 JP 7185524B2 JP 2018513423 A JP2018513423 A JP 2018513423A JP 2018513423 A JP2018513423 A JP 2018513423A JP 7185524 B2 JP7185524 B2 JP 7185524B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
val
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018513423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535647A5 (enExample
JP2018535647A (ja
Inventor
トラン、エリック
ルー、ヨン－チェン
エー． ローゼンバーグ、スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2018535647A publication Critical patent/JP2018535647A/ja
Publication of JP2018535647A5 publication Critical patent/JP2018535647A5/ja
Priority to JP2022188263A priority Critical patent/JP7461445B2/ja
Application granted granted Critical
Publication of JP7185524B2 publication Critical patent/JP7185524B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
JP2018513423A 2015-09-15 2016-09-09 Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 Active JP7185524B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022188263A JP7461445B2 (ja) 2015-09-15 2022-11-25 Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562218688P 2015-09-15 2015-09-15
US62/218,688 2015-09-15
PCT/US2016/050875 WO2017048593A1 (en) 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022188263A Division JP7461445B2 (ja) 2015-09-15 2022-11-25 Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体

Publications (3)

Publication Number Publication Date
JP2018535647A JP2018535647A (ja) 2018-12-06
JP2018535647A5 JP2018535647A5 (enExample) 2019-10-17
JP7185524B2 true JP7185524B2 (ja) 2022-12-07

Family

ID=56985686

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018513423A Active JP7185524B2 (ja) 2015-09-15 2016-09-09 Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体
JP2022188263A Active JP7461445B2 (ja) 2015-09-15 2022-11-25 Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022188263A Active JP7461445B2 (ja) 2015-09-15 2022-11-25 Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体

Country Status (14)

Country Link
US (3) US10556940B2 (enExample)
EP (2) EP3901169A1 (enExample)
JP (2) JP7185524B2 (enExample)
KR (2) KR20250117744A (enExample)
CN (2) CN115073583A (enExample)
AU (3) AU2016323017B2 (enExample)
CA (1) CA2998869A1 (enExample)
DK (1) DK3350213T3 (enExample)
ES (1) ES2879287T3 (enExample)
IL (1) IL257840B2 (enExample)
MX (1) MX2018003062A (enExample)
SA (1) SA518391109B1 (enExample)
SG (1) SG10201913868XA (enExample)
WO (1) WO2017048593A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2557123B (en) 2015-07-31 2021-11-03 Univ Minnesota Modified cells and methods of therapy
LT3494133T (lt) * 2016-08-02 2022-12-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t ląstelės receptoriai
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP3602053B1 (en) * 2017-03-31 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of isolating neoantigen-specific t cell receptor sequences
EP3635000A4 (en) * 2017-05-16 2021-04-14 The Johns Hopkins University Manabodies and methods of using
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
SG11202002425PA (en) * 2017-09-20 2020-04-29 The United States Of America As Represented By The Secretary Hla class ii-restricted t cell receptors against mutated ras
AU2018345400B2 (en) 2017-10-05 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
CN111836638B (zh) * 2017-12-04 2024-10-29 美国卫生和人力服务部 针对突变的ras的hla i类限制性t细胞受体
CA3103983A1 (en) 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
US12331097B2 (en) * 2018-08-16 2025-06-17 Biontech Us Inc. T cell receptor constructs and uses thereof
CN113412277B (zh) * 2019-01-22 2025-07-18 美国卫生和人力服务部 针对含有g12r突变的ras的hla第ii类限制性t细胞受体
GB2596461B (en) 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
US20210342750A1 (en) * 2019-08-14 2021-11-04 Nec Corporation Information processing apparatus, information processing method, and storage medium
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
WO2021163477A1 (en) * 2020-02-14 2021-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against ras with g12v mutation
CN111574616B (zh) * 2020-06-17 2021-02-02 深圳豪石生物科技有限公司 分离的t细胞受体和应用
EP4182029A1 (en) * 2020-07-16 2023-05-24 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii-restricted drb t cell receptors against ras with g12v mutation
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
US20240175047A1 (en) 2021-02-25 2024-05-30 Alaunos Therapeutics, Inc. Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541332A (ja) 2010-09-20 2013-11-14 ビオエンテッヒ・アクチェンゲゼルシャフト 抗原特異的ｔ細胞受容体およびｔ細胞エピトープ
JP2014528714A (ja) 2011-09-15 2014-10-30 アメリカ合衆国 Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体
WO2015022520A1 (en) 2013-08-12 2015-02-19 Immunocore Limited T cell receptors
JP2017536825A (ja) 2014-11-26 2017-12-14 アメリカ合衆国 抗突然変異ｋｒａｓ ｔ細胞受容体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
ES2842878T3 (es) * 2005-08-05 2021-07-15 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Generación de células T específicas de antígeno
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541332A (ja) 2010-09-20 2013-11-14 ビオエンテッヒ・アクチェンゲゼルシャフト 抗原特異的ｔ細胞受容体およびｔ細胞エピトープ
JP2014528714A (ja) 2011-09-15 2014-10-30 アメリカ合衆国 Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体
WO2015022520A1 (en) 2013-08-12 2015-02-19 Immunocore Limited T cell receptors
JP2017536825A (ja) 2014-11-26 2017-12-14 アメリカ合衆国 抗突然変異ｋｒａｓ ｔ細胞受容体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, (2015), Vol.112, No.3, pp.779-784, published January 20, 2015

Also Published As

Publication number Publication date
MX2018003062A (es) 2018-09-11
KR20250117744A (ko) 2025-08-05
AU2021200833B2 (en) 2022-04-28
JP2023025108A (ja) 2023-02-21
CN108350059B (zh) 2021-10-08
KR20180044428A (ko) 2018-05-02
US20200148739A1 (en) 2020-05-14
US20190040111A1 (en) 2019-02-07
EP3901169A1 (en) 2021-10-27
JP7461445B2 (ja) 2024-04-03
ES2879287T3 (es) 2021-11-22
EP3350213A1 (en) 2018-07-25
IL257840A (en) 2018-04-30
US11667692B2 (en) 2023-06-06
IL257840B1 (en) 2023-06-01
AU2016323017B2 (en) 2020-11-12
WO2017048593A1 (en) 2017-03-23
US20230406904A1 (en) 2023-12-21
JP2018535647A (ja) 2018-12-06
CA2998869A1 (en) 2017-03-23
SA518391109B1 (ar) 2022-02-14
AU2021200833A1 (en) 2021-03-04
KR102841067B1 (ko) 2025-08-01
US10556940B2 (en) 2020-02-11
CN108350059A (zh) 2018-07-31
AU2022209229A1 (en) 2022-09-15
SG10201913868XA (en) 2020-03-30
IL257840B2 (en) 2023-10-01
CN115073583A (zh) 2022-09-20
AU2022209229B2 (en) 2024-05-23
EP3350213B1 (en) 2021-03-31
AU2016323017A1 (en) 2018-04-05
DK3350213T3 (da) 2021-06-21
HK1257902A1 (en) 2019-11-01

Similar Documents

Publication Publication Date Title
JP7461445B2 (ja) Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体
US11840561B2 (en) Anti-KRAS-G12D T cell receptors
AU2017258745B2 (en) Anti-KK-LC-1 T cell receptors
JP7635165B2 (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
US20230312672A1 (en) Hla class i-restricted t cell receptors against cd20
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras
WO2022225836A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190902

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221125

R150 Certificate of patent or registration of utility model

Ref document number: 7185524

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250